Merck, which is expanding plant in Durham, reports bigger profits
The Associated Press
Merck is the process of expanding its production facility in Durham, N.C.
The maker of cholesterol drugs, vaccines and asthma and allergy treatment Singulair said net income was $3.42 billion, more than triple the $1.09 billion it made a year earlier.
That’s mostly due to Merck having to sell its half of the Merial animal health business so that regulators would approve its plan to buy New Jersey neighbor Schering-Plough Corp.
That sale brought in $2.8 billion, or $1.7 billion after taxes. Without it, profit would have been up roughly 58 percent from the 2008 third quarter.
Whitehouse Station, N.J.-based Merck is about to leapfrog from No. 8 to No. 2 in the pharmaceutical industry with its pending $41.1 billion acquisition of Schering-Plough. That will put it right behind Pfizer Inc., which last week bought Wyeth for $68 billion.
“We have made significant progress in our planning the past three months” for the merger, Chief Executive Richard Clark told analysts during a conference call. “We will be ready to hit the ground running on our first day of business as the new Merck.”
For the third quarter, Merck posted a 2 percent increase in revenue, to $6.05 billion.
It had earnings per share of $1.61, or 90 cents excluding the big gain from Merial. That beat analysts’ conservative expectations for earnings per share of 82 cents without items and revenue of $6 billion.
Please Log In to add a comment.
Best of TechWire Insider
- 'Let's talk tech jobs:' What's really happening in IT hiring?
- Star Trek gets real: Durham startup delivers interactive holograms
- Every tech company needs to join 'Global Government Surveillance Reform' movement
- Durham entrepreneurs find ally in Charlotte medtech incubator
- GoGown deal shows power, necessity of networking for startups
- New GSK oncology consortium targets combination therapies
- Fighting hospital infections: A Durham nurse's dream produces the GoGown
- From photos to out-of-this-world art: Raleigh firm's software transforms images
- LabCorp expands gene tests for cancer - but don't confuse these with 23andMe
- ChannelAdvisor: Mobile cuts deeply into PC share of online shopping